STOCK TITAN
  1. Home
  2. Sec-filings
  3. PTGX
  4. [Form 4] Protagonist Therapeutics, Inc Insider Trading Activity

Protagonist Therapeutics (PTGX) CEO granted 95,400 RSUs and 120,200 options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel reported equity awards on Form 4. On January 2, 2026, he received 95,400 shares of common stock as a grant of restricted stock units at a stated price of $0. These units are payable solely in common stock and will vest in four equal annual installments on January 15, 2027, 2028, 2029 and 2030, contingent on his continued service.

On the same date he was also granted a stock option for 120,200 shares of common stock with an exercise price of $87.18. This option vests in 48 equal monthly installments following January 2, 2026, also subject to continued service, and had 120,200 derivative securities beneficially owned after the transaction. Following the restricted stock grant, he beneficially owned 614,943 shares of common stock directly.

Positive

  • None.

Negative

  • None.
Insider PATEL DINESH V PH D
Role President and CEO
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 120,200 $0.00 --
Grant/Award Common Stock 95,400 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 120,200 shares (Direct); Common Stock — 614,943 shares (Direct)
Footnotes (1)
  1. Represents grant of restricted stock units payable solely in common stock that will vest in four equal annual installments on January 15, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The stock option vests in 48 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PATEL DINESH V PH D
(Last) (First) (Middle)
C/O PROTAGONIST THERAPEUTICS, INC.
7707 GATEWAY BLVD., SUITE 140
(Street)
NEWARK CA 94560-1160
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/02/2026 A 95,400(1) A $0 614,943 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $87.18 01/02/2026 A 120,200 (2) 01/02/2036 Common Stock 120,200 $0 120,200 D
Explanation of Responses:
1. Represents grant of restricted stock units payable solely in common stock that will vest in four equal annual installments on January 15, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
2. The stock option vests in 48 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
/s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D. 01/06/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did PTGX President and CEO Dinesh V. Patel report?

Dinesh V. Patel reported two equity awards dated January 2, 2026: a grant of 95,400 restricted stock units payable in common stock at a stated price of $0, and a stock option for 120,200 shares of common stock with an exercise price of $87.18.

How do the 95,400 Protagonist Therapeutics (PTGX) RSUs vest for the CEO?

The 95,400 restricted stock units will vest in four equal annual installments on January 15, 2027, 2028, 2029 and 2030, and each installment requires Dinesh V. Patel to continue serving the company through the applicable vesting date.

What are the vesting terms of the 120,200-share stock option reported by PTGX’s CEO?

The stock option for 120,200 shares of common stock, with an exercise price of $87.18, vests in 48 equal monthly installments following January 2, 2026, subject to Dinesh V. Patel’s continued service through each vesting date.

How many PTGX common shares did the CEO beneficially own after this Form 4 transaction?

After the January 2, 2026 grant of restricted stock units, Dinesh V. Patel beneficially owned 614,943 shares of Protagonist Therapeutics common stock directly.

Were the reported PTGX equity awards to the CEO direct or indirect holdings?

Both the 95,400 restricted stock units and the 120,200-share stock option are reported as direct (D) ownership by Dinesh V. Patel, with no separate nature of indirect ownership noted.

What role does the reporting person hold at Protagonist Therapeutics (PTGX)?

The reporting person, Dinesh V. Patel, Ph.D., is identified as both a Director and an Officer, serving as President and CEO of Protagonist Therapeutics, Inc.